

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 10-817-US)**

In re Application of:)	
)	
J. Crowley, et al.)	
)	Group Art Unit: 1651
Serial No.: 10/591,118)	
)	Examiner: Barnhart, L.E.
Filed: September 28, 2007)	
)	Confirm. No.: 7739
For: Process for Cell Culturing by Continuous) Perfusion and Alternating Tangential Flow)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references are enclosed herewith. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

This Information Disclosure Statement is being filed:

**McDonnell, Boehnen, Hulbert & Berghoff LLP
300 S. Wacker Drive, Suite 3100
Chicago, IL 60606
312-913-0001**

☒ within three months of the filing date of a national application; within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or before the mailing date of a first Office Action on the merits. 37 C.F.R. § 1.97 (b)

☐ **after** three months of the filing date of a national application, or the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or **after** the mailing date of a first Office Action on the merits, but **before** the mailing date of a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311 (whichever occurs first), and includes (37 C.F.R. § 1.97 (c):

☐ the Certification under 37 C.F.R. § 1.97(e) (see “Certification” below)

OR

☐ the fee of \$180 set forth in 37 C.F.R. § 1.17(p) (see “Fees” below).

☐ **after** a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311 (whichever occurs first), but before, or simultaneously with, the payment of the issue fee, and includes the Certification under 37 C.F.R. § 1.97(e) (see “Certification” below), and the Petition Fee set forth in 37 C.F.R. § 1.17(i) (see “Fees” and “Method of Payment of Fees” below). Applicants hereby petitions for consideration of the Information Disclosure Statement submitted herewith and the accompanying references in examination of the subject patent application.

CERTIFICATION

☐ The **undersigned** hereby certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.

☐ The **undersigned** hereby certifies that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

FEES

McDonnell, Boehnen, Hulbert & Berghoff LLP
300 S. Wacker Drive, Suite 3100
Chicago, IL 60606
312-913-0001

- ☒ **No fee** is owed by the applicant(s).
☐ The **IDS Fee of \$180.00** under 37 C.F.R. § 1.17(p) is enclosed herewith.

METHOD OF PAYMENT OF FEES

- ☐ Charge Deposit Account No. 13-2490 in the amount of \$180.00.

Please charge any underpayment or credit any overpayment in connection with this communication to Deposit Account No. 13-2490.

Respectfully submitted,

/David S. Harper/
David S. Harper, Ph.D.
Registration No. 42,636

US Patent Documents

1. Liu et al., United States Patent No. 6,168,941, Issued January 2, 2001.
2. Hateboer, et al., United States Patent No. 6855544, Issued February 15, 2005.
3. Sasaki et al., United States Patent Publication No. 20030134388, Published July 17, 2003.

Foreign Patent Documents

4. Celltech Limited, WO 1993005145, Published March 18, 1993.
5. Smith, et al., EP 1 157 098, Published September 17, 2008.
6. Cell Biologics, WO 2003025158, Published March 27, 2003.
7. Cru-Cell Holland B.V., WO 2004099396, Published November 18, 2004.
8. DSM IP Assets, WO 2005095578, Published October 13, 2005.
9. DSM IP Assets, WO 2008006494, Published January 17, 2008.

Other Documents

10. Mercille, et al. (2004) Biotechnology and Bioengineering, 43(9): 833-846.
11. Kruse, et al., (1965) The Journal of Cell Biology, 27: 273-279.

McDonnell, Boehnen, Hulbert & Berghoff LLP
300 S. Wacker Drive, Suite 3100
Chicago, IL 60606
312-913-0001

12. Jordan, et al, (1992)"Tuning of shear sensitivity of CHO cells and its correlation with the size distribution of cell aggregates" in Animal cell technology: developments, processes and products, eds. Spier, R.E., Griffiths, J.B. and MacDonald, C. London: Butterworth-Heinemann, pp 418-20.
13. Snabre, et al., (1987) Biophys. J., 51: 795-807.
14. Moreira, et al., (1992) "Aggregate suspension cultures of BHK cells" in Animal cell technology: developments, processes and products, eds. Spier, R.E., Griffiths, J.B. and MacDonald, C. London: Butterworth-Heinemann, pp 41 1-413.
15. Maiorella, et al., (1991) Biotechnol. Bioeng., 37(2): 121-126.
16. A/G Technology Corporation, "Operating Guide" January 1999, NG Technology Corporation
17. Yun-Seung Kyung, et al., (1994) Cytotechnology, 14: 183-190.
18. Anthony S. Lubiniecki, "Large-scale mammalian cell culture technology", CRC Press, 1990, pages 237-240.
19. Gary C. Howard, et al., "Basic Methods in Antibody Production and Characterization", CRC Press, 2000, page 91.
20. Michael A. Winkler, "Chemical engineering problems in biotechnology", Published by Springer, 1990, pages 329-330.
21. Terence Cartwright, "Animal cells as bioreactors", Cambridge University Press, 1994, pages 72-86.
22. Shepherd, et al., "Monoclonal antibodies: a practical approach", Oxford University Press, 2000, pages 137-138.
23. Maureen Anne Harrison and Ian Fraser Rae, "General techniques of cell culture", Cambridge University Press, 1997, page 128.
24. E.C. Beuvery, et al., "Animal Cell Technology: Developments Towards the 21st Century", Springer, 1995, page 554.

25. Jerry Shevitz, et al, "Stirred tank perfusion reactors for cell propagation and monoclonal antibody production" in "Advances in Biotechnological Processes" (1989), Alan R. Liss, Inc., Chapter 11, pages 81-106.
26. Jones, D. et al., (2003) *Biotechnol. Prog.* 19: 163-168.
27. Fallaux et al., (1998). *Hum Gene Ther.* 9(13): 1909-17.
28. Furey, J. "Continuous and Scalable Production from a Bioreactor" Poster presentation at the Cell Culture Engineering VII conference, Snowmass Village, Colorado, United States of America, 1-6 April 2002.
29. Furey, J. (2002) *Genetic Engineering News*, 22(7): 62-63.
30. Bleckwenn, N.A., Bentley, W. and Shiloach, J. "Production and Glycosylation Analysis of Model proteins from Vaccinia Virus-Mammalian Expression System", poster presentation at the 18th meeting of the European Society for Animal Cell technology (ESACT), Granada, Spain, 11-14 May 2003.
31. Bleckwenn N.A. et al., "Scalable Protein Production in Anchorage Dependent Mammalian Cells", poster presentation at Bioscience day conference, 2003.
32. Bleckwenn N.A. et al., entitled "Expression of EGFP Reporter protein with a Recombinant Vaccinia Virus – Comparison of Microcarrier and Cell Suspension Based Bioreactor Systems" poster presentation at meeting of the American Chemical Society, 2003.
33. Press release: "Scalable and Reliable Perfusion – Is It Really Possible?" published in the United Kingdom, 17 April 2002.
34. Statutory Declaration of Vaughan Barlow from corresponding case AU 2005229359, June 30, 2010,
35. Statutory Declaration of Jerry Shevitz from corresponding case AU 2005229359, April 27, 2010.
36. Statutory Declaration of V. Chiruvolu from corresponding case AU 2005229359, June 2, 2010.
37. Second Statutory Declaration of V. Chiruvolu from corresponding case AU 2005229359, June 2, 2010

38. Statutory Declaration of Sol Genauer from corresponding case AU 2005229359, July 2, 2010.
39. Statutory Declaration of Michael Doran from corresponding case AU 2005229359, June 28, 2010.
40. Belfort, et al., (1994), "New Development in Membrane Bioreactors," Membrane Processes in Separation and Purification, eds. Crespo and Boddeker, pages 127-148.
41. Fuchs, et al., (2002) Journal of Biotechnology, 93:243-251.
42. Griffiths (2000), "Immobilized Cultures," Animal Cell Culture: A Practical Approach, Oxford University Press, eds Masters et al., page 58-67.
43. Harrison, et al, (1997), General Techniques of cell culture, Cambridge University Press, page 122-138.
44. Horwath, (1995) "Facility Design and Validation Considerations for Continuous Cell Culture Processes," Animal Cell Technology: Developments Towards the 21st Century, Springer, eds. Reuvery, et al., page 553-559.
45. Maranga, et al., (2006) Biotechnology and Bioengineering, 94(1): 139-150.
46. Norris, et al.,(2002) "Growth of Cell Lines in Bioreactors," Basic Methods in Antibody Production and Characterization, CRC Press, eds. Howard, et al., page 87-103.
47. Portner, et al., (1995) "Evaluation of Process Strategies for efficient cultivation of hybridoma cells based on mathematical models," Animal Cell Technology: Developments Towards the 21st Century, Springer, eds. Reuvery, et al., page 829-831.
48. Risenberg, et al., (1999) Appl Microbiol Biotechnol, 51:422-430.
49. Xie, et al., (2002) Biotechnology and Bioengineering, 80(5): 569-579.

Respectfully submitted,

Date: /July 23, 2010/

/David S. Harper/
David S. Harper, Ph.D.

McDonnell, Boehnen, Hulbert & Berghoff LLP
300 S. Wacker Drive, Suite 3100
Chicago, IL 60606
312-913-0001

Registration No. 42,636

Telephone: 312-913-0001
Facsimile: 312-913-0002

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, IL 60606

McDonnell, Boehnen, Hulbert & Berghoff LLP
300 S. Wacker Drive, Suite 3100
Chicago, IL 60606
312-913-0001